"NPJ Vaccines"[ Journal] - Search Results

Year	Number of Results
2016	16
2017	36
2018	55
2019	54
2020	112
2021	158
2022	174
2023	81

1

ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.

Castro JT, Brito R, Hojo-Souza NS, Azevedo B, Salazar N, Ferreira CP, Junqueira C, Fernandes AP, Vasconcellos R, Cardoso JM, Aguiar-Soares RDO, Vieira PMA, Carneiro CM, Valiate B, Toledo C, Salazar AM, Caballero O, Lannes-Vieira J, Teixeira SR, Reis AB, Gazzinelli RT. Castro JT, et al. NPJ Vaccines. 2023 May 31;8(1):81. doi: 10.1038/s41541-023-00676-0. NPJ Vaccines. 2023. PMID: 37258518 Free PMC article.

2

Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization.

Prior JT, Limbert VM, Horowitz RM, D'Souza SJ, Bachnak L, Godwin MS, Bauer DL, Harrell JE, Morici LA, Taylor JJ, McLachlan JB. Prior JT, et al. NPJ Vaccines. 2023 May 31;8(1):80. doi: 10.1038/s41541-023-00677-z. NPJ Vaccines. 2023. PMID: 37258506 Free PMC article.

3

Immunization against arthropod protein impairs transmission of rickettsial pathogen from ticks to the vertebrate host.

Mahesh PP, Namjoshi P, Sultana H, Neelakanta G. Mahesh PP, et al. NPJ Vaccines. 2023 May 30;8(1):79. doi: 10.1038/s41541-023-00678-y. NPJ Vaccines. 2023. PMID: 37253745 Free PMC article.

4

Assessment of African swine fever vaccine candidate ASFV-G-∆MGF in a reversion to virulence study.

Deutschmann P, Forth JH, Sehl-Ewert J, Carrau T, Viaplana E, Mancera JC, Urniza A, Beer M, Blome S. Deutschmann P, et al. NPJ Vaccines. 2023 May 29;8(1):78. doi: 10.1038/s41541-023-00669-z. NPJ Vaccines. 2023. PMID: 37248243 Free PMC article.

5

DNA based neoepitope vaccination induces tumor control in syngeneic mouse models.

Viborg N, Pavlidis MA, Barrio-Calvo M, Friis S, Trolle T, Sørensen AB, Thygesen CB, Kofoed SV, Kleine-Kohlbrecher D, Hadrup SR, Rønø B. Viborg N, et al. NPJ Vaccines. 2023 May 27;8(1):77. doi: 10.1038/s41541-023-00671-5. NPJ Vaccines. 2023. PMID: 37244905 Free PMC article.

6

Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa.

Wang X, Liu C, Rcheulishvili N, Papukashvili D, Xie F, Zhao J, Hu X, Yu K, Yang N, Pan X, Liu X, Wang PG, He Y. Wang X, et al. NPJ Vaccines. 2023 May 25;8(1):76. doi: 10.1038/s41541-023-00672-4. NPJ Vaccines. 2023. PMID: 37231060 Free PMC article.

7

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.

LeFevre I, Bravo L, Folschweiller N, Medina EL, Moreira ED Jr, Nordio F, Sharma M, Tharenos LM, Tricou V, Watanaveeradej V, Winkle PJ, Biswal S. LeFevre I, et al. NPJ Vaccines. 2023 May 25;8(1):75. doi: 10.1038/s41541-023-00670-6. NPJ Vaccines. 2023. PMID: 37230978 Free PMC article.

8

Developmental and reproductive toxicity of a recombinant protein subunit COVID-19 vaccine (ZF2001) in rats.

Song Y, Shao J, She G, Lv W, Chen G, Liu J, Zhang L, Zhang C, Wang J, Tian R, Dai L, Gao GF, Huang E, Zhang L. Song Y, et al. NPJ Vaccines. 2023 May 24;8(1):74. doi: 10.1038/s41541-023-00673-3. NPJ Vaccines. 2023. PMID: 37225729 Free PMC article.

9

GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus.

Scher G, Bente DA, Mears MC, Cajimat MNB, Schnell MJ. Scher G, et al. NPJ Vaccines. 2023 May 20;8(1):73. doi: 10.1038/s41541-023-00663-5. NPJ Vaccines. 2023. PMID: 37210392 Free PMC article.

10

A candidate subunit vaccine induces protective immunity against Mycobacterium avium subspecies paratuberculosis in mice.

Shao M, Cui N, Tang Y, Chen F, Cui Y, Dang G, Liu S. Shao M, et al. NPJ Vaccines. 2023 May 20;8(1):72. doi: 10.1038/s41541-023-00675-1. NPJ Vaccines. 2023. PMID: 37210376 Free PMC article.

11

Calibration of a serum reference standard for Group B streptococcal polysaccharide conjugate vaccine development using surface plasmon resonance.

Esadze A, Grube CD, Wellnitz S, Singh S, Nguyen HH, Gaylord MA, Zhu A, Gribenko A, Tan CY, Anderson AS, Simon R. Esadze A, et al. NPJ Vaccines. 2023 May 19;8(1):71. doi: 10.1038/s41541-023-00667-1. NPJ Vaccines. 2023. PMID: 37208375 Free PMC article.

12

Th₁-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses.

den Hartog Y, Malahe SRK, Rietdijk WJR, Dieterich M, Gommers L, Geers D, Bogers S, van Baarle D, Diavatopoulos DA, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Bemelman FJ, Gansevoort RT, Hilbrands LB, Sanders JS, GeurtsvanKessel CH, Kho MML, Reinders MEJ, de Vries RD, Baan CC; RECOVAC Consortium. den Hartog Y, et al. NPJ Vaccines. 2023 May 17;8(1):70. doi: 10.1038/s41541-023-00664-4. NPJ Vaccines. 2023. PMID: 37198189 Free PMC article.

13

Global economic burden per episode for multiple diseases caused by group A Streptococcus.

Lee JS, Kim S, Excler JL, Kim JH, Mogasale V. Lee JS, et al. NPJ Vaccines. 2023 May 15;8(1):69. doi: 10.1038/s41541-023-00659-1. NPJ Vaccines. 2023. PMID: 37188693 Free PMC article.

14

Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection.

Diallo BK, Ní Chasaide C, Wong TY, Schmitt P, Lee KS, Weaver K, Miller O, Cooper M, Jazayeri SD, Damron FH, Mills KHG. Diallo BK, et al. NPJ Vaccines. 2023 May 13;8(1):68. doi: 10.1038/s41541-023-00665-3. NPJ Vaccines. 2023. PMID: 37179389 Free PMC article.

15

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Ponce-de-León S, et al. NPJ Vaccines. 2023 May 10;8(1):67. doi: 10.1038/s41541-023-00662-6. NPJ Vaccines. 2023. PMID: 37164959 Free PMC article.

16

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG.

Dijkman K, Lindenstrøm T, Rosenkrands I, Søe R, Woodworth JS, Lindestam Arlehamn CS, Mortensen R. Dijkman K, et al. NPJ Vaccines. 2023 May 9;8(1):66. doi: 10.1038/s41541-023-00666-2. NPJ Vaccines. 2023. PMID: 37160970 Free PMC article.

17

Microfluidic cell squeeze-based vaccine comes into clinical investigation.

Wang S, Yang Y, Zha Y, Li N. Wang S, et al. NPJ Vaccines. 2023 May 4;8(1):65. doi: 10.1038/s41541-023-00641-x. NPJ Vaccines. 2023. PMID: 37142615 Free PMC article. No abstract available.

18

Risk assessment of retinal vascular occlusion after COVID-19 vaccination.

Li JX, Wang YH, Bair H, Hsu SB, Chen C, Wei JC, Lin CJ. Li JX, et al. NPJ Vaccines. 2023 May 2;8(1):64. doi: 10.1038/s41541-023-00661-7. NPJ Vaccines. 2023. PMID: 37130882 Free PMC article.

19

Immunization with a Trypanosoma cruzi cyclophilin-19 deletion mutant protects against acute Chagas disease in mice.

Jha BK, Varikuti S, Verma C, Shivahare R, Bishop N, Dos Santos GP, McDonald J, Sur A, Myler PJ, Schenkman S, Satoskar AR, McGwire BS. Jha BK, et al. NPJ Vaccines. 2023 Apr 25;8(1):63. doi: 10.1038/s41541-023-00647-5. NPJ Vaccines. 2023. PMID: 37185599 Free PMC article.

20

Optimal global spending for group A Streptococcus vaccine research and development.

Tortorice D, Ferranna M, Bloom DE. Tortorice D, et al. NPJ Vaccines. 2023 Apr 25;8(1):62. doi: 10.1038/s41541-023-00646-6. NPJ Vaccines. 2023. PMID: 37185380 Free PMC article.

21

Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort.

Bürzle O, Menges D, Maier JD, Schams D, Puhan MA, Fehr J, Ballouz T, Frei A. Bürzle O, et al. NPJ Vaccines. 2023 Apr 24;8(1):61. doi: 10.1038/s41541-023-00657-3. NPJ Vaccines. 2023. PMID: 37095137 Free PMC article.

22

Resistance to COVID-19 vaccination and the social contract: evidence from Italy.

Kreps SE, Kriner DL. Kreps SE, et al. NPJ Vaccines. 2023 Apr 22;8(1):60. doi: 10.1038/s41541-023-00660-8. NPJ Vaccines. 2023. PMID: 37087511 Free PMC article.

23

Modalities of group A streptococcal prevention and treatment and their economic justification.

Cannon JW, Wyber R. Cannon JW, et al. NPJ Vaccines. 2023 Apr 22;8(1):59. doi: 10.1038/s41541-023-00649-3. NPJ Vaccines. 2023. PMID: 37087467 Free PMC article.

24

Long-term humoral response following Delta and Omicron BA.1 co-infection.

Saade C, Pozzetto B, Yaugel-Novoa M, Oriol G, Josset L, Lina B, Paul S, Bal A, Trouillet-Assant S. Saade C, et al. NPJ Vaccines. 2023 Apr 20;8(1):57. doi: 10.1038/s41541-023-00652-8. NPJ Vaccines. 2023. PMID: 37080996 Free PMC article.

25

An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection.

Bollman B, Nunna N, Bahl K, Hsiao CJ, Bennett H, Butler S, Foreman B, Burgomaster KE, Aleshnick M, Kong WP, Fisher BE, Ruckwardt TJ, Morabito KM, Graham BS, Dowd KA, Pierson TC, Carfi A. Bollman B, et al. NPJ Vaccines. 2023 Apr 20;8(1):58. doi: 10.1038/s41541-023-00656-4. NPJ Vaccines. 2023. PMID: 37080988 Free PMC article.

26

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles.

MacDonald NJ, Singh K, Reiter K, Nguyen V, Shimp R Jr, Gittis AG, Chen B, Burkhardt M, Zhang B, Wang Z, Herrera R, Moler M, Lee DY, Orr-Gonzalez S, Herrod J, Lambert LE, Rausch KM, Muratova O, Jones DS, Wu Y, Jin AJ, Garboczi DN, Duffy PE, Narum DL. MacDonald NJ, et al. NPJ Vaccines. 2023 Apr 15;8(1):56. doi: 10.1038/s41541-023-00655-5. NPJ Vaccines. 2023. PMID: 37061547 Free PMC article.

27

Is new dengue vaccine efficacy data a relief or cause for concern?

Thomas SJ. Thomas SJ. NPJ Vaccines. 2023 Apr 15;8(1):55. doi: 10.1038/s41541-023-00658-2. NPJ Vaccines. 2023. PMID: 37061527 Free PMC article. Review.

28

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report.

Knisely JM, Buyon LE, Mandt R, Farkas R, Balasingam S, Bok K, Buchholz UJ, D'Souza MP, Gordon JL, King DFL, Le TT, Leitner WW, Seder RA, Togias A, Tollefsen S, Vaughn DW, Wolfe DN, Taylor KL, Fauci AS. Knisely JM, et al. NPJ Vaccines. 2023 Apr 12;8(1):53. doi: 10.1038/s41541-023-00654-6. NPJ Vaccines. 2023. PMID: 37045860 Free PMC article.

29

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans.

Viviani V, Fantoni A, Tomei S, Marchi S, Luzzi E, Bodini M, Muzzi A, Giuliani MM, Maione D, Derrick JP, Delany I, Pizza M, Biolchi A, Bartolini E. Viviani V, et al. NPJ Vaccines. 2023 Apr 12;8(1):54. doi: 10.1038/s41541-023-00651-9. NPJ Vaccines. 2023. PMID: 37045859 Free PMC article.

30

Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.

Ludwig J, Scally SW, Costa G, Hoffmann S, Murugan R, Lossin J, Prieto K, Obraztcova A, Lobeto N, Franke-Fayard B, Janse CJ, Lebas C, Collin N, Binter S, Kellam P, Levashina EA, Wardemann H, Julien JP. Ludwig J, et al. NPJ Vaccines. 2023 Apr 7;8(1):52. doi: 10.1038/s41541-023-00653-7. NPJ Vaccines. 2023. PMID: 37029167 Free PMC article.

31

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.

Tarrés-Freixas F, Aguilar-Gurrieri C, Rodríguez de la Concepción ML, Urrea V, Trinité B, Ortiz R, Pradenas E, Blanco P, Marfil S, Molinos-Albert LM, Barajas A, Pons-Grífols A, Ávila-Nieto C, Varela I, Cervera L, Gutiérrez-Granados S, Segura MM, Gòdia F, Clotet B, Carrillo J, Blanco J. Tarrés-Freixas F, et al. NPJ Vaccines. 2023 Apr 6;8(1):51. doi: 10.1038/s41541-023-00648-4. NPJ Vaccines. 2023. PMID: 37024469 Free PMC article.

32

An effective live-attenuated Zika vaccine candidate with a modified 5' untranslated region.

Nazneen F, Thompson EA, Blackwell C, Bai JS, Huang F, Bai F. Nazneen F, et al. NPJ Vaccines. 2023 Apr 1;8(1):50. doi: 10.1038/s41541-023-00650-w. NPJ Vaccines. 2023. PMID: 37005424 Free PMC article.

33

Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy.

Goon P, Sauzet O, Schuermann M, Oppel F, Shao S, Scholtz LU, Sudhoff H, Goerner M. Goon P, et al. NPJ Vaccines. 2023 Apr 1;8(1):49. doi: 10.1038/s41541-023-00644-8. NPJ Vaccines. 2023. PMID: 37005390 Free PMC article.

34

Progress towards a glycoconjugate vaccine against Group A Streptococcus.

Burns K, Dorfmueller HC, Wren BW, Mawas F, Shaw HA. Burns K, et al. NPJ Vaccines. 2023 Mar 28;8(1):48. doi: 10.1038/s41541-023-00639-5. NPJ Vaccines. 2023. PMID: 36977677 Free PMC article. Review.

35

Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice.

Cotter CA, Americo JL, Earl PL, Moss B. Cotter CA, et al. NPJ Vaccines. 2023 Mar 27;8(1):47. doi: 10.1038/s41541-023-00645-7. NPJ Vaccines. 2023. PMID: 36973267 Free PMC article.

36

A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9.

Hörner C, Fiedler AH, Bodmer BS, Walz L, Scheuplein VA, Hutzler S, Matrosovich MN, von Messling V, Mühlebach MD. Hörner C, et al. NPJ Vaccines. 2023 Mar 24;8(1):46. doi: 10.1038/s41541-023-00643-9. NPJ Vaccines. 2023. PMID: 36964176 Free PMC article.

37

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.

Saeland E, van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, van Polanen Y, Vaneman C, Tettero L, Cox F, Serroyen J, Jorgensen MJ, Langedijk JPM, Schuitemaker H, Callendret B, Zahn RC. Saeland E, et al. NPJ Vaccines. 2023 Mar 23;8(1):45. doi: 10.1038/s41541-023-00637-7. NPJ Vaccines. 2023. PMID: 36949051 Free PMC article.

38

Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity.

Patra T, Meyer K, Haga Y, Reagan EK, Weissman D, Ray R. Patra T, et al. NPJ Vaccines. 2023 Mar 18;8(1):42. doi: 10.1038/s41541-023-00635-9. NPJ Vaccines. 2023. PMID: 36934116 Free PMC article.

39

SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies.

Shrivastava S, Carmen JM, Lu Z, Basu S, Sankhala RS, Chen WH, Nguyen P, Chang WC, King J, Corbitt C, Mayer S, Bolton JS, Anderson A, Swafford I, Terriquez GD, Trinh HV, Kim J, Jobe O, Paquin-Proulx D, Matyas GR, Gromowski GD, Currier JR, Bergmann-Leitner E, Modjarrad K, Michael NL, Joyce MG, Malloy AMW, Rao M. Shrivastava S, et al. NPJ Vaccines. 2023 Mar 18;8(1):43. doi: 10.1038/s41541-023-00638-6. NPJ Vaccines. 2023. PMID: 36934088 Free PMC article.

40

Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination.

Yu-Ping Z, Jing L, Teng H, Zhi-Fang Y, Ting Z, Yan-Chun C, Zhi-Mei Z, Yu-Ting F, Jun-Hui T, Qing-Hai Y, Ding-Kai W, Guo-Liang L, Xiao-Lei Y, Li Y, Hong-Bo C, Jian-Feng W, Rui-Ju J, Lei Y, Wei C, Wei Y, Ming-Xue X, Qiong-Zhou Y, Jing P, Li S, Chao H, Yan D, Lu-Kui C, Jian Z, Yu W, Hong-Sen L, Wei H, Zhao-Jun M, Chang-Gui L, Qi-Han L, Jing-Si Y. Yu-Ping Z, et al. NPJ Vaccines. 2023 Mar 18;8(1):44. doi: 10.1038/s41541-023-00642-w. NPJ Vaccines. 2023. PMID: 36934085 Free PMC article.

41

Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants.

Wussow F, Kha M, Kim T, Ly M, Yll-Pico M, Kar S, Lewis MG, Chiuppesi F, Diamond DJ. Wussow F, et al. NPJ Vaccines. 2023 Mar 16;8(1):41. doi: 10.1038/s41541-023-00640-y. NPJ Vaccines. 2023. PMID: 36928589 Free PMC article.

42

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.

Swart M, van der Lubbe J, Schmit-Tillemans S, van Huizen E, Verspuij J, Gil AI, Choi Y, Daal C, Perkasa A, de Wilde A, Claassen E, de Jong R, Wiese KE, Cornelissen L, van Es M, van Heerden M, Kourkouta E, Tahiri I, Mulders M, Vreugdenhil J, Feddes-de Boer K, Muchene L, Tolboom J, Dekking L, Juraszek J, Vellinga J, Custers J, Bos R, Schuitemaker H, Wegmann F, Roozendaal R, Kuipers H, Zahn R. Swart M, et al. NPJ Vaccines. 2023 Mar 16;8(1):40. doi: 10.1038/s41541-023-00633-x. NPJ Vaccines. 2023. PMID: 36927774 Free PMC article.

43

PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application.

Zhang Z, Zhou J, Ni P, Hu B, Jolicoeur N, Deng S, Xiao Q, He Q, Li G, Xia Y, Liu M, Wang C, Fang Z, Xia N, Zhang ZR, Zhang B, Cai K, Xu Y, Liu B. Zhang Z, et al. NPJ Vaccines. 2023 Mar 15;8(1):38. doi: 10.1038/s41541-023-00636-8. NPJ Vaccines. 2023. PMID: 36922524 Free PMC article.

44

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.

Roy V, Jung W, Linde C, Coates E, Ledgerwood J, Costner P, Yamshchikov G, Streeck H, Juelg B, Lauffenburger DA, Alter G. Roy V, et al. NPJ Vaccines. 2023 Mar 15;8(1):39. doi: 10.1038/s41541-023-00628-8. NPJ Vaccines. 2023. PMID: 36922512 Free PMC article.

45

A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection.

Howlader DR, Das S, Lu T, Mandal RS, Hu G, Varisco DJ, Dietz ZK, Ratnakaram SSK, Ernst RK, Picking WD, Picking WL. Howlader DR, et al. NPJ Vaccines. 2023 Mar 14;8(1):37. doi: 10.1038/s41541-023-00618-w. NPJ Vaccines. 2023. PMID: 36918600 Free PMC article.

46

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.

Benkeser D, Fong Y, Janes HE, Kelly EJ, Hirsch I, Sproule S, Stanley AM, Maaske J, Villafana T, Houchens CR, Martins K, Jayashankar L, Castellino F, Ayala V, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Isaacs MB, Makhene M, Tong T, Robb ML, Corey L, Neuzil KM, Follmann D, Hoffman C, Falsey AR, Sobieszczyk M, Koup RA, Donis RO, Gilbert PB; AstraZeneca AZD1222 Clinical Study Group; Immune Assays Team; United States Government (USG)/CoVPN Biostatistics Team. Benkeser D, et al. NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0. NPJ Vaccines. 2023. PMID: 36899062 Free PMC article.

47

A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults.

Meron-Sudai S, Asato V, Adler A, Bialik A, Goren S, Ariel-Cohen O, Reizis A, Mulard LA, Phalipon A, Cohen D. Meron-Sudai S, et al. NPJ Vaccines. 2023 Mar 10;8(1):35. doi: 10.1038/s41541-023-00624-y. NPJ Vaccines. 2023. PMID: 36894570 Free PMC article.

48

Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.

Loos C, Coccia M, Didierlaurent AM, Essaghir A, Fallon JK, Lauffenburger D, Luedemann C, Michell A, van der Most R, Zhu AL, Alter G, Burny W. Loos C, et al. NPJ Vaccines. 2023 Mar 8;8(1):34. doi: 10.1038/s41541-023-00613-1. NPJ Vaccines. 2023. PMID: 36890168 Free PMC article.

49

Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination.

Uwamino Y, Nagashima K, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M. Uwamino Y, et al. NPJ Vaccines. 2023 Mar 6;8(1):33. doi: 10.1038/s41541-023-00626-w. NPJ Vaccines. 2023. PMID: 36878929 Free PMC article.

50

Predicting indirect effects of rotavirus vaccination programs on rotavirus mortality among children in 112 countries.

Kraay ANM, Chaney DM, Deshpande A, Pitzer VE, Lopman BA. Kraay ANM, et al. NPJ Vaccines. 2023 Mar 4;8(1):32. doi: 10.1038/s41541-023-00632-y. NPJ Vaccines. 2023. PMID: 36871093 Free PMC article.

51

Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models.

Medina-Magües LG, Mühe J, Jasny E, Medina-Magües ES, Roth N, Lopera-Madrid J, Salas-Quinchucua C, Knuese C, Petsch B, Osorio JE. Medina-Magües LG, et al. NPJ Vaccines. 2023 Mar 4;8(1):31. doi: 10.1038/s41541-023-00629-7. NPJ Vaccines. 2023. PMID: 36871059 Free PMC article.

52

Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice.

Nanishi E, Borriello F, Seo HS, O'Meara TR, McGrath ME, Saito Y, Chen J, Diray-Arce J, Song K, Xu AZ, Barman S, Menon M, Dong D, Caradonna TM, Feldman J, Hauser BM, Schmidt AG, Baden LR, Ernst RK, Dillen C, Yu J, Chang A, Hilgers L, Platenburg PP, Dhe-Paganon S, Barouch DH, Ozonoff A, Zanoni I, Frieman MB, Dowling DJ, Levy O. Nanishi E, et al. NPJ Vaccines. 2023 Mar 3;8(1):30. doi: 10.1038/s41541-023-00634-w. NPJ Vaccines. 2023. PMID: 36869134 Free PMC article. No abstract available.

53

Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality.

Laeremans T, den Roover S, Lungu C, D'haese S, Gruters RA, Allard SD, Aerts JL. Laeremans T, et al. NPJ Vaccines. 2023 Mar 2;8(1):29. doi: 10.1038/s41541-023-00631-z. NPJ Vaccines. 2023. PMID: 36864042 Free PMC article.

54

Mobilizing domestic support for international vaccine solidarity - recommendations for health crisis communication.

Leuffen D, Mounchid PM, Heermann M, Koos S. Leuffen D, et al. NPJ Vaccines. 2023 Feb 28;8(1):28. doi: 10.1038/s41541-023-00625-x. NPJ Vaccines. 2023. PMID: 36854782 Free PMC article. No abstract available.

55

Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice.

Hassan AS, Houle S, Labrie L, Perera DJ, Dozois CM, Ward BJ, Ndao M. Hassan AS, et al. NPJ Vaccines. 2023 Feb 27;8(1):27. doi: 10.1038/s41541-023-00599-w. NPJ Vaccines. 2023. PMID: 36849453 Free PMC article.

56

Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination.

Holt H, Jolliffe DA, Talaei M, Faustini S, Vivaldi G, Greenig M, Richter AG, Lyons RA, Griffiths CJ, Kee F, Sheikh A, Davies GA, Shaheen SO, Martineau AR. Holt H, et al. NPJ Vaccines. 2023 Feb 25;8(1):26. doi: 10.1038/s41541-023-00614-0. NPJ Vaccines. 2023. PMID: 36841835 Free PMC article.

57

Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice.

Afkhami S, D'Agostino MR, Vaseghi-Shanjani M, Lepard M, Yang JX, Lai R, Choi MWY, Chacon A, Zganiacz A, Franken KLMC, Ertl HC, Ottenhoff THM, Jeyanathan M, Gillgrass A, Xing Z. Afkhami S, et al. NPJ Vaccines. 2023 Feb 23;8(1):25. doi: 10.1038/s41541-023-00623-z. NPJ Vaccines. 2023. PMID: 36823425 Free PMC article.

58

Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes.

Milne C, Wagner R, Cano F, Bruysters M, Waeterloos G, Pullirsch D, Wierer M, Mallet L. Milne C, et al. NPJ Vaccines. 2023 Feb 23;8(1):22. doi: 10.1038/s41541-023-00617-x. NPJ Vaccines. 2023. PMID: 36823287 Free PMC article. Review.

59

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques.

Jacob-Dolan C, Yu J, McMahan K, Giffin V, Chandrashekar A, Martinot AJ, Anioke T, Powers OC, Hall K, Hope D, Miller J, Hachmann NP, Chung B, Gardner S, Sellers D, Barrett J, Lewis MG, Andersen H, Kleanthous H, Seo KW, Lee SJ, Park YW, Kim H, Barouch DH. Jacob-Dolan C, et al. NPJ Vaccines. 2023 Feb 23;8(1):23. doi: 10.1038/s41541-023-00622-0. NPJ Vaccines. 2023. PMID: 36823160 Free PMC article.

60

The immunological interplay between vaccination and the intestinal microbiota.

Zimmermann P. Zimmermann P. NPJ Vaccines. 2023 Feb 23;8(1):24. doi: 10.1038/s41541-023-00627-9. NPJ Vaccines. 2023. PMID: 36823142 Free PMC article. No abstract available.

61

Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children.

Tsang TK, Wang C, Tsang NNY, Fang VJ, Perera RAPM, Malik Peiris JS, Leung GM, Cowling BJ, Ip DKM. Tsang TK, et al. NPJ Vaccines. 2023 Feb 20;8(1):21. doi: 10.1038/s41541-023-00621-1. NPJ Vaccines. 2023. PMID: 36804941 Free PMC article.

62

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine.

Dickey TH, Gupta R, McAleese H, Ouahes T, Orr-Gonzalez S, Ma R, Muratova O, Salinas ND, Hume JCC, Lambert LE, Duffy PE, Tolia NH. Dickey TH, et al. NPJ Vaccines. 2023 Feb 18;8(1):20. doi: 10.1038/s41541-023-00619-9. NPJ Vaccines. 2023. PMID: 36808125 Free PMC article.

63

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions.

Fisher KJ, Kinsey R, Mohamath R, Phan T, Liang H, Orr MT, Lykins WR, Guderian JA, Bakken J, Argilla D, Ramer-Denisoff G, Larson E, Qi Y, Sivananthan S, Smolyar K, Carter D, Paddon CJ, Fox CB. Fisher KJ, et al. NPJ Vaccines. 2023 Feb 16;8(1):14. doi: 10.1038/s41541-023-00608-y. NPJ Vaccines. 2023. PMID: 36797262 Free PMC article.

64

Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.

Vatzia E, Feest K, McNee A, Manjegowda T, Carr BV, Paudyal B, Chrun T, Maze EA, Mccarron A, Morris S, Everett HE, MacLoughlin R, Salguero FJ, Lambe T, Gilbert SC, Tchilian E. Vatzia E, et al. NPJ Vaccines. 2023 Feb 15;8(1):19. doi: 10.1038/s41541-023-00620-2. NPJ Vaccines. 2023. PMID: 36792640 Free PMC article.

65

QuilA® adjuvanted Coxevac® sustains Th1-CD8⁺-type immunity and increases protection in Coxiella burnetii-challenged goats.

Tomaiuolo S, Jansen W, Soares Martins S, Devriendt B, Cox E, Mori M. Tomaiuolo S, et al. NPJ Vaccines. 2023 Feb 14;8(1):17. doi: 10.1038/s41541-023-00607-z. NPJ Vaccines. 2023. PMID: 36788233 Free PMC article.

66

The Streptococcus pyogenes vaccine landscape.

Walkinshaw DR, Wright MEE, Mullin AE, Excler JL, Kim JH, Steer AC. Walkinshaw DR, et al. NPJ Vaccines. 2023 Feb 14;8(1):16. doi: 10.1038/s41541-023-00609-x. NPJ Vaccines. 2023. PMID: 36788225 Free PMC article. Review.

67

Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice.

Nanishi E, Borriello F, Seo HS, O'Meara TR, McGrath ME, Saito Y, Chen J, Diray-Arce J, Song K, Xu AZ, Barman S, Menon M, Dong D, Caradonna TM, Feldman J, Hauser BM, Schmidt AG, Baden LR, Ernst RK, Dillen C, Yu J, Chang A, Hilgers L, Platenburg PP, Dhe-Paganon S, Barouch DH, Ozonoff A, Zanoni I, Frieman MB, Dowling DJ, Levy O. Nanishi E, et al. NPJ Vaccines. 2023 Feb 14;8(1):18. doi: 10.1038/s41541-023-00610-4. NPJ Vaccines. 2023. PMID: 36788219 Free PMC article.

68

Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19.

Kaplonek P, Cizmeci D, Lee JS, Shin SA, Fischinger S, Gobeil P, Pillet S, Charland N, Ward BJ, Alter G. Kaplonek P, et al. NPJ Vaccines. 2023 Feb 13;8(1):13. doi: 10.1038/s41541-023-00612-2. NPJ Vaccines. 2023. PMID: 36781879 Free PMC article.

69

Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.

Azevedo PO, Hojo-Souza NS, Faustino LP, Fumagalli MJ, Hirako IC, Oliveira ER, Figueiredo MM, Carvalho AF, Doro D, Benevides L, Durigon E, Fonseca F, Machado AM, Fernandes AP, Teixeira SR, Silva JS, Gazzinelli RT. Azevedo PO, et al. NPJ Vaccines. 2023 Feb 13;8(1):15. doi: 10.1038/s41541-023-00616-y. NPJ Vaccines. 2023. PMID: 36781862 Free PMC article.

70

Generation of a high yield vaccine backbone for influenza B virus in embryonated chicken eggs.

Aslam S, Rajendran M, Kriti D, Kurland A, Johnson J, van Bakel H, Krammer F, García-Sastre A, Ayllon J. Aslam S, et al. NPJ Vaccines. 2023 Feb 10;8(1):12. doi: 10.1038/s41541-023-00603-3. NPJ Vaccines. 2023. PMID: 36765053 Free PMC article.

71

A scrub typhus vaccine presents a challenging unmet need.

Walker DH, Mendell NL. Walker DH, et al. NPJ Vaccines. 2023 Feb 9;8(1):11. doi: 10.1038/s41541-023-00605-1. NPJ Vaccines. 2023. PMID: 36759505 Free PMC article. Review.

72

Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge.

Yankowski C, Kurup D, Wirblich C, Schnell MJ. Yankowski C, et al. NPJ Vaccines. 2023 Feb 8;8(1):10. doi: 10.1038/s41541-023-00615-z. NPJ Vaccines. 2023. PMID: 36754965 Free PMC article.

73

Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model.

Reynolds S, Rafeek RAM, Hamlin A, Lepletier A, Pandey M, Ketheesan N, Good MF. Reynolds S, et al. NPJ Vaccines. 2023 Feb 4;8(1):9. doi: 10.1038/s41541-023-00604-2. NPJ Vaccines. 2023. PMID: 36739443 Free PMC article.

74

Maternal antibodies induced by a live attenuated vaccine protect neonatal mice from cytomegalovirus.

Le-Trilling VTK, Jagnjić A, Brizić I, Eilbrecht M, Wohlgemuth K, Rožmanić C, Herdman A, Hoffmann K, Westendorf AM, Hengel H, Jonjić S, Trilling M. Le-Trilling VTK, et al. NPJ Vaccines. 2023 Feb 3;8(1):8. doi: 10.1038/s41541-023-00602-4. NPJ Vaccines. 2023. PMID: 36737485 Free PMC article.

75

Author Correction: "World in motion" - emulsion adjuvants rising to meet the pandemic challenges.

O'Hagan DT, van der Most R, Lodaya RN, Coccia M, Lofano G. O'Hagan DT, et al. NPJ Vaccines. 2023 Feb 2;8(1):7. doi: 10.1038/s41541-023-00601-5. NPJ Vaccines. 2023. PMID: 36732535 Free PMC article. No abstract available.

76

Is partisan conflict over COVID-19 vaccination eroding support for childhood vaccine mandates?

Motta M. Motta M. NPJ Vaccines. 2023 Feb 2;8(1):5. doi: 10.1038/s41541-023-00611-3. NPJ Vaccines. 2023. PMID: 36732345 Free PMC article. No abstract available.

77

Immunological correlates of protection following vaccination with glucan particles containing Cryptococcus neoformans chitin deacetylases.

Wang R, Oliveira LVN, Lourenco D, Gomez CL, Lee CK, Hester MM, Mou Z, Ostroff GR, Specht CA, Levitz SM. Wang R, et al. NPJ Vaccines. 2023 Feb 2;8(1):6. doi: 10.1038/s41541-023-00606-0. NPJ Vaccines. 2023. PMID: 36732332 Free PMC article.

78

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K, Thomassen KS, Kro GB, Cox RJ, Zhou F, Langeland N, Aukrust P, Melum E, Åvitsland TL, Wiencke K, Holter JC, Munthe LA, Grødeland G, Andersen JT, Vaage JT, Lund-Johansen F. Tran TT, et al. NPJ Vaccines. 2023 Jan 25;8(1):4. doi: 10.1038/s41541-023-00600-6. NPJ Vaccines. 2023. PMID: 36697432 Free PMC article. No abstract available.

79

Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy.

Teymournejad O, Li Z, Beesetty P, Yang C, Montgomery CP. Teymournejad O, et al. NPJ Vaccines. 2023 Jan 24;8(1):3. doi: 10.1038/s41541-022-00598-3. NPJ Vaccines. 2023. PMID: 36693884 Free PMC article.

80

Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine.

Deng JZ, Kuster N, Drumheller A, Lin M, Ansbro F, Grozdanovic M, Samuel R, Zhuang P. Deng JZ, et al. NPJ Vaccines. 2023 Jan 23;8(1):2. doi: 10.1038/s41541-022-00584-9. NPJ Vaccines. 2023. PMID: 36690697 Free PMC article.

81

Correlates of immunity to Group A Streptococcus: a pathway to vaccine development.

Frost H, Excler JL, Sriskandan S, Fulurija A. Frost H, et al. NPJ Vaccines. 2023 Jan 17;8(1):1. doi: 10.1038/s41541-022-00593-8. NPJ Vaccines. 2023. PMID: 36650164 Free PMC article. Review.

82

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K, Thomassen KS, Kro GB, Cox RJ, Zhou F, Langeland N, Aukrust P, Melum E, Åvitsland TL, Wiencke K, Holter JC, Munthe LA, Grødeland G, Andersen JT, Vaage JT, Lund-Johansen F. Tran TT, et al. NPJ Vaccines. 2022 Dec 30;7(1):174. doi: 10.1038/s41541-022-00586-7. NPJ Vaccines. 2022. PMID: 36585405 Free PMC article.

83

Factors influencing long-term persistence of anti-HBs after hepatitis B vaccination.

Fonzo M, Bertoncello C, Trevisan A. Fonzo M, et al. NPJ Vaccines. 2022 Dec 26;7(1):173. doi: 10.1038/s41541-022-00596-5. NPJ Vaccines. 2022. PMID: 36572682 Free PMC article.

84

A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines.

Gomez AM, Babuadze GG, Plourde-Campagna MA, Azizi H, Berger A, Kozak R, de La Vega MA, Xiii A, Naghibosadat M, Nepveu-Traversy ME, Ruel J, Kobinger GP. Gomez AM, et al. NPJ Vaccines. 2022 Dec 22;7(1):172. doi: 10.1038/s41541-022-00581-y. NPJ Vaccines. 2022. PMID: 36543794 Free PMC article.

85

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.

van Doremalen N, Avanzato VA, Goldin K, Feldmann F, Schulz JE, Haddock E, Okumura A, Lovaglio J, Hanley PW, Cordova K, Saturday G, de Wit E, Lambe T, Gilbert SC, Munster VJ. van Doremalen N, et al. NPJ Vaccines. 2022 Dec 21;7(1):171. doi: 10.1038/s41541-022-00592-9. NPJ Vaccines. 2022. PMID: 36543806 Free PMC article.

86

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern.

Shi J, Wang G, Zheng J, Verma AK, Guan X, Malisheni MM, Geng Q, Li F, Perlman S, Du L. Shi J, et al. NPJ Vaccines. 2022 Dec 19;7(1):169. doi: 10.1038/s41541-022-00580-z. NPJ Vaccines. 2022. PMID: 36535987 Free PMC article.

87

Challenges and developments in universal vaccine design against SARS-CoV-2 variants.

Zhao F, Zai X, Zhang Z, Xu J, Chen W. Zhao F, et al. NPJ Vaccines. 2022 Dec 19;7(1):167. doi: 10.1038/s41541-022-00597-4. NPJ Vaccines. 2022. PMID: 36535982 Free PMC article. Review.

88

A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine.

Desai S, Anil K, Potey AV, Sindhu Y, Grappi S, Lapini G, Manney S, Tyagi P, Montomoli E, Poonawalla CS, Kulkarni PS. Desai S, et al. NPJ Vaccines. 2022 Dec 19;7(1):170. doi: 10.1038/s41541-022-00595-6. NPJ Vaccines. 2022. PMID: 36535976 Free PMC article.

89

RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses.

Su C, Zhong Y, Zhao G, Hou J, Zhang S, Wang B. Su C, et al. NPJ Vaccines. 2022 Dec 19;7(1):168. doi: 10.1038/s41541-022-00591-w. NPJ Vaccines. 2022. PMID: 36535957 Free PMC article.

90

Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses.

Ithinji DG, Buchholz DW, Ezzatpour S, Monreal IA, Cong Y, Sahler J, Bangar AS, Imbiakha B, Upadhye V, Liang J, Ma A, Bradel-Tretheway B, Kaza B, Yeo YY, Choi EJ, Johnston GP, Huzella L, Kollins E, Dixit S, Yu S, Postnikova E, Ortega V, August A, Holbrook MR, Aguilar HC. Ithinji DG, et al. NPJ Vaccines. 2022 Dec 17;7(1):166. doi: 10.1038/s41541-022-00588-5. NPJ Vaccines. 2022. PMID: 36528644 Free PMC article.

91

Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques.

Roy CJ, Ehrbar D, Van Slyke G, Doering J, Didier PJ, Doyle-Meyers L, Donini O, Vitetta ES, Mantis NJ. Roy CJ, et al. NPJ Vaccines. 2022 Dec 16;7(1):164. doi: 10.1038/s41541-022-00582-x. NPJ Vaccines. 2022. PMID: 36526642 Free PMC article.

92

Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial.

Liu LT, Chiu CH, Chiu NC, Tan BF, Lin CY, Cheng HY, Lin MY, Lien CE, Chen C, Huang LM. Liu LT, et al. NPJ Vaccines. 2022 Dec 16;7(1):165. doi: 10.1038/s41541-022-00589-4. NPJ Vaccines. 2022. PMID: 36526640 Free PMC article.

93

A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malaria.

Moita D, Maia TG, Duarte M, Andrade CM, Albuquerque IS, Dwivedi A, Silva JC, González-Céron L, Janse CJ, Mendes AM, Prudêncio M. Moita D, et al. NPJ Vaccines. 2022 Dec 16;7(1):163. doi: 10.1038/s41541-022-00585-8. NPJ Vaccines. 2022. PMID: 36526627 Free PMC article.

94

Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic.

Huang L, Lai FTT, Yan VKC, Cheng FWT, Cheung CL, Chui CSL, Li X, Wan EYF, Wong CKH, Hung IFN, Lau CS, Wong ICK, Chan EWY. Huang L, et al. NPJ Vaccines. 2022 Dec 15;7(1):162. doi: 10.1038/s41541-022-00594-7. NPJ Vaccines. 2022. PMID: 36522341 Free PMC article.

95

A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine.

Low JG, de Alwis R, Chen S, Kalimuddin S, Leong YS, Mah TKL, Yuen N, Tan HC, Zhang SL, Sim JXY, Chan YFZ, Syenina A, Yee JX, Ong EZ, Sekulovich R, Sullivan BB, Lindert K, Sullivan SM, Chivukula P, Hughes SG, Ooi EE. Low JG, et al. NPJ Vaccines. 2022 Dec 13;7(1):161. doi: 10.1038/s41541-022-00590-x. NPJ Vaccines. 2022. PMID: 36513697 Free PMC article.

96

Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination.

Aydillo T, Gonzalez-Reiche AS, Stadlbauer D, Amper MA, Nair VD, Mariottini C, Sealfon SC, van Bakel H, Palese P, Krammer F, García-Sastre A. Aydillo T, et al. NPJ Vaccines. 2022 Dec 10;7(1):160. doi: 10.1038/s41541-022-00583-w. NPJ Vaccines. 2022. PMID: 36496417 Free PMC article.

97

Urgency and necessity of Epstein-Barr virus prophylactic vaccines.

Zhong L, Krummenacher C, Zhang W, Hong J, Feng Q, Chen Y, Zhao Q, Zeng MS, Zeng YX, Xu M, Zhang X. Zhong L, et al. NPJ Vaccines. 2022 Dec 9;7(1):159. doi: 10.1038/s41541-022-00587-6. NPJ Vaccines. 2022. PMID: 36494369 Free PMC article. Review.

98

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children.

Bartsch YC, Chen JW, Kang J, Burns MD, St Denis KJ, Sheehan ML, Davis JP, Edlow AG, Balazs AB, Yonker LM, Alter G. Bartsch YC, et al. NPJ Vaccines. 2022 Dec 3;7(1):158. doi: 10.1038/s41541-022-00575-w. NPJ Vaccines. 2022. PMID: 36463314 Free PMC article.

99

Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis.

Karmakar S, Volpedo G, Zhang WW, Lypaczewski P, Ismail N, Oliveira F, Oristian J, Meneses C, Gannavaram S, Kamhawi S, Hamano S, Valenzuela JG, Matlashewski G, Satoskar AR, Dey R, Nakhasi HL. Karmakar S, et al. NPJ Vaccines. 2022 Dec 3;7(1):157. doi: 10.1038/s41541-022-00574-x. NPJ Vaccines. 2022. PMID: 36463228 Free PMC article.

100

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum.

Hayashi CTH, Cao Y, Clark LC, Tripathi AK, Zavala F, Dwivedi G, Knox J, Alameh MG, Lin PJC, Tam YK, Weissman D, Kumar N. Hayashi CTH, et al. NPJ Vaccines. 2022 Dec 1;7(1):155. doi: 10.1038/s41541-022-00577-8. NPJ Vaccines. 2022. PMID: 36456563 Free PMC article.

101

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.

Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop JN, Roozendaal R, Van Effelterre T, Gaddah A, Van Roey GA, Solforosi L, Zahn R, Callendret B, Hendriks J, Luhn K, Douoguih M, Schuitemaker H, Van Hoof J. Bockstal V, et al. NPJ Vaccines. 2022 Nov 30;7(1):156. doi: 10.1038/s41541-022-00564-z. NPJ Vaccines. 2022. PMID: 36450746 Free PMC article.

102

Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine.

Ong EZ, Yee JX, Ooi JSG, Syenina A, de Alwis R, Chen S, Sim JXY, Kalimuddin S, Leong YS, Chan YFZ, Sekulovich R, Sullivan BM, Lindert K, Sullivan SB, Chivukula P, Hughes SG, Low JG, Ooi EE, Chan KR. Ong EZ, et al. NPJ Vaccines. 2022 Nov 28;7(1):154. doi: 10.1038/s41541-022-00573-y. NPJ Vaccines. 2022. PMID: 36443317 Free PMC article.

103

A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles.

Nakao R, Kobayashi H, Iwabuchi Y, Kawahara K, Hirayama S, Ramstedt M, Sasaki Y, Kataoka M, Akeda Y, Ohnishi M. Nakao R, et al. NPJ Vaccines. 2022 Nov 26;7(1):153. doi: 10.1038/s41541-022-00572-z. NPJ Vaccines. 2022. PMID: 36435869 Free PMC article.

104

Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates.

Reiss EIMM, van Haaren MM, van Schooten J, Claireaux MAF, Maisonnasse P, Antanasijevic A, Allen JD, Bontjer I, Torres JL, Lee WH, Ozorowski G, Vázquez Bernat N, Kaduk M, Aldon Y, Burger JA, Chawla H, Aartse A, Tolazzi M, Gao H, Mundsperger P, Crispin M, Montefiori DC, Karlsson Hedestam GB, Scarlatti G, Ward AB, Le Grand R, Shattock R, Dereuddre-Bosquet N, Sanders RW, van Gils MJ. Reiss EIMM, et al. NPJ Vaccines. 2022 Nov 25;7(1):152. doi: 10.1038/s41541-022-00576-9. NPJ Vaccines. 2022. PMID: 36433972 Free PMC article.

105

Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.

Voigt EA, Gerhardt A, Hanson D, Jennewein MF, Battisti P, Reed S, Singh J, Mohamath R, Bakken J, Beaver S, Press C, Soon-Shiong P, Paddon CJ, Fox CB, Casper C. Voigt EA, et al. NPJ Vaccines. 2022 Nov 23;7(1):150. doi: 10.1038/s41541-022-00578-7. NPJ Vaccines. 2022. PMID: 36418864 Free PMC article. No abstract available.

106

Author Correction: Selectively targeting haemagglutinin antigen to chicken CD83 receptor induces faster and stronger immunity against avian influenza.

Shrestha A, Sadeyen JR, Lukosaityte D, Chang P, Smith A, Van Hulten M, Iqbal M. Shrestha A, et al. NPJ Vaccines. 2022 Nov 23;7(1):151. doi: 10.1038/s41541-022-00579-6. NPJ Vaccines. 2022. PMID: 36418329 Free PMC article. No abstract available.

107

Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination.

Byazrova MG, Astakhova EA, Minnegalieva AR, Sukhova MM, Mikhailov AA, Prilipov AG, Gorchakov AA, Filatov AV. Byazrova MG, et al. NPJ Vaccines. 2022 Nov 15;7(1):145. doi: 10.1038/s41541-022-00566-x. NPJ Vaccines. 2022. PMID: 36379998 Free PMC article.

108

Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers.

Prentoe J, Janitzek CM, Velázquez-Moctezuma R, Soerensen A, Jørgensen T, Clemmensen S, Soroka V, Thrane S, Theander T, Nielsen MA, Salanti A, Bukh J, Sander AF. Prentoe J, et al. NPJ Vaccines. 2022 Nov 15;7(1):148. doi: 10.1038/s41541-022-00570-1. NPJ Vaccines. 2022. PMID: 36379958 Free PMC article.

109

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.

Khan S, Salisch NC, Gil AI, Boedhoe S, Boer KF, Serroyen J, Schuitemaker H, Zahn RC. Khan S, et al. NPJ Vaccines. 2022 Nov 15;7(1):146. doi: 10.1038/s41541-022-00567-w. NPJ Vaccines. 2022. PMID: 36379957 Free PMC article.

110

Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases.

Intapiboon P, Uae-Areewongsa P, Ongarj J, Sophonmanee R, Seepathomnarong P, Seeyankem B, Surasombatpattana S, Pinpathomrat N. Intapiboon P, et al. NPJ Vaccines. 2022 Nov 15;7(1):149. doi: 10.1038/s41541-022-00568-9. NPJ Vaccines. 2022. PMID: 36379939 Free PMC article.

111

Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant.

Sitaras I, Jacobsen H, Higdon MM, Dowling WE, Bar-Zeev N, Deloria Knoll M. Sitaras I, et al. NPJ Vaccines. 2022 Nov 15;7(1):147. doi: 10.1038/s41541-022-00565-y. NPJ Vaccines. 2022. PMID: 36379935 Free PMC article.

112

A potent, broadly protective vaccine against SARS-CoV-2 variants of concern.

Wang Z, An J, Liu K, Yu P, Fang X, Li J, Zhu H, Zhu Q, Huang C, Zhang C, Zhao B, Bao L, Song Y, Cao X, Hu D, Jiang Y, Shi L, Zhou L, Fan J, Guan W, Zhou C, Hu Z, Yuan Z, Liu J, Shan C, Liu G. Wang Z, et al. NPJ Vaccines. 2022 Nov 12;7(1):144. doi: 10.1038/s41541-022-00571-0. NPJ Vaccines. 2022. PMID: 36371432 Free PMC article.

113

Bordetella pertussis whole cell immunization protects against Pseudomonas aeruginosa infections.

Blackwood CB, Mateu-Borrás M, Sen-Kilic E, Pyles GM, Miller SJ, Weaver KL, Witt WT, Huckaby AB, Kang J, Chandler CE, Ernst RK, Heath Damron F, Barbier M. Blackwood CB, et al. NPJ Vaccines. 2022 Nov 10;7(1):143. doi: 10.1038/s41541-022-00562-1. NPJ Vaccines. 2022. PMID: 36357402 Free PMC article.

114

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Charland N, Gobeil P, Pillet S, Boulay I, Séguin A, Makarkov A, Heizer G, Bhutada K, Mahmood A, Trépanier S, Hager K, Jiang-Wright J, Atkins J, Saxena P, Cheng MP, Vinh DC, Boutet P, Roman F, Van Der Most R, Ceregido MA, Dionne M, Tellier G, Gauthier JS, Essink B, Libman M, Haffizulla J, Fréchette A, D'Aoust MA, Landry N, Ward BJ. Charland N, et al. NPJ Vaccines. 2022 Nov 9;7(1):142. doi: 10.1038/s41541-022-00561-2. NPJ Vaccines. 2022. PMID: 36351931 Free PMC article.

115

Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.

Buoninfante A, Andeweg A, Baker AT, Borad M, Crawford N, Dogné JM, Garcia-Azorin D, Greinacher A, Helfand R, Hviid A, Kochanek S, López-Fauqued M, Nazy I, Padmanabhan A, Pavord S, Prieto-Alhambra D, Tran H, Wandel Liminga U, Cavaleri M. Buoninfante A, et al. NPJ Vaccines. 2022 Nov 9;7(1):141. doi: 10.1038/s41541-022-00569-8. NPJ Vaccines. 2022. PMID: 36351906 Free PMC article.

116

Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data.

Ryman J, Weaver J, Hu T, Weinberger DM, Yee KL, Sachs JR. Ryman J, et al. NPJ Vaccines. 2022 Nov 7;7(1):140. doi: 10.1038/s41541-022-00538-1. NPJ Vaccines. 2022. PMID: 36344529 Free PMC article.

117

Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis.

Jayawardana S, Weerasuriya CK, Pelzer PT, Seeley J, Harris RC, Tameris M, Tait D, White RG, Asaria M. Jayawardana S, et al. NPJ Vaccines. 2022 Nov 7;7(1):138. doi: 10.1038/s41541-022-00554-1. NPJ Vaccines. 2022. PMID: 36344523 Free PMC article.

118

Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver.

Franke-Fayard B, Marin-Mogollon C, Geurten FJA, Chevalley-Maurel S, Ramesar J, Kroeze H, Baalbergen E, Wessels E, Baron L, Soulard V, Martinson T, Aleshnick M, Huijs ATG, Subudhi AK, Miyazaki Y, Othman AS, Kolli SK, Lamers OAC, Roques M, Stanway RR, Murphy SC, Foquet L, Moita D, Mendes AM, Prudêncio M, Dechering KJ, Heussler VT, Pain A, Wilder BK, Roestenberg M, Janse CJ. Franke-Fayard B, et al. NPJ Vaccines. 2022 Nov 4;7(1):139. doi: 10.1038/s41541-022-00558-x. NPJ Vaccines. 2022. PMID: 36333336 Free PMC article.

119

Yellow fever resurgence: An avoidable crisis?

Lindsey NP, Horton J, Barrett ADT, Demanou M, Monath TP, Tomori O, Van Herp M, Zeller H, Fall IS, Cibrelus L, Erin Staples J. Lindsey NP, et al. NPJ Vaccines. 2022 Nov 2;7(1):137. doi: 10.1038/s41541-022-00552-3. NPJ Vaccines. 2022. PMID: 36323723 Free PMC article. No abstract available.

120

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.

Voigt EA, Gerhardt A, Hanson D, Jennewein MF, Battisti P, Reed S, Singh J, Mohamath R, Bakken J, Beaver S, Press C, Soon-Shiong P, Paddon CJ, Fox CB, Casper C. Voigt EA, et al. NPJ Vaccines. 2022 Nov 2;7(1):136. doi: 10.1038/s41541-022-00549-y. NPJ Vaccines. 2022. PMID: 36323666 Free PMC article.

121

DYNAMIC cohort study evaluating metabolic predictors of influenza vaccine immune response in older adults.

Sadarangani SP, Young BE, Lian W, Phua HP, Chen MI, Barr I, Yeo TW, Dalan R, Chow A. Sadarangani SP, et al. NPJ Vaccines. 2022 Nov 1;7(1):135. doi: 10.1038/s41541-022-00548-z. NPJ Vaccines. 2022. PMID: 36319665 Free PMC article.

122

TAFA4-IL-10 axis potentiate immunotherapy for airway allergy by induction of specific regulatory T cells.

Qiu S, Luo X, Mo L, Zhang S, Liao Y, Guan L, Yang L, Huang Q, Liu D, Yang P. Qiu S, et al. NPJ Vaccines. 2022 Oct 31;7(1):133. doi: 10.1038/s41541-022-00559-w. NPJ Vaccines. 2022. PMID: 36316414 Free PMC article.

123

Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70.

Qian C, Yang Y, Xu Q, Wang Z, Chen J, Chi X, Yu M, Gao F, Xu Y, Lu Y, Sun H, Shen J, Wang D, Zhou L, Li T, Wang Y, Zheng Q, Yu H, Zhang J, Gu Y, Xia N, Li S. Qian C, et al. NPJ Vaccines. 2022 Oct 31;7(1):134. doi: 10.1038/s41541-022-00557-y. NPJ Vaccines. 2022. PMID: 36316367 Free PMC article.

124

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.

Friberg H, Gargulak M, Kong A, Lin L, Martinez LJ, Schmidt AC, Paris RM, Jarman RG, Diaz C, Thomas SJ, Moris P, Currier JR. Friberg H, et al. NPJ Vaccines. 2022 Oct 31;7(1):132. doi: 10.1038/s41541-022-00537-2. NPJ Vaccines. 2022. PMID: 36316335 Free PMC article.

125

B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs.

Gavitt TD, Mara AB, Goodridge ML, Ozyck RG, Reinhardt E, Miller JM, Hunte M, Tulman ER, Frasca S Jr, Silbart LK, Geary SJ, Szczepanek SM. Gavitt TD, et al. NPJ Vaccines. 2022 Oct 31;7(1):130. doi: 10.1038/s41541-022-00556-z. NPJ Vaccines. 2022. PMID: 36310317 Free PMC article.

126

Toxoplasmosis vaccines: what we have and where to go?

Zhang Y, Li D, Lu S, Zheng B. Zhang Y, et al. NPJ Vaccines. 2022 Oct 31;7(1):131. doi: 10.1038/s41541-022-00563-0. NPJ Vaccines. 2022. PMID: 36310233 Free PMC article. Review.

127

Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates.

Seenappa LM, Jakubowski A, Steinbuck MP, Palmer E, Haqq CM, Carter C, Fontenot J, Villinger F, McNeil LK, DeMuth PC. Seenappa LM, et al. NPJ Vaccines. 2022 Oct 28;7(1):128. doi: 10.1038/s41541-022-00560-3. NPJ Vaccines. 2022. PMID: 36307453 Free PMC article.

128

Immune correlates of protection following Rift Valley fever virus vaccination.

Doyle JD, Barbeau DJ, Cartwright HN, McElroy AK. Doyle JD, et al. NPJ Vaccines. 2022 Oct 28;7(1):129. doi: 10.1038/s41541-022-00551-4. NPJ Vaccines. 2022. PMID: 36307416 Free PMC article.

129

Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children.

Zheng Z, Weinberger DM, Pitzer VE. Zheng Z, et al. NPJ Vaccines. 2022 Oct 27;7(1):127. doi: 10.1038/s41541-022-00550-5. NPJ Vaccines. 2022. PMID: 36302926 Free PMC article.

130

Sterile protection against relapsing malaria with a single-shot vaccine.

Pasini EM, van der Wel AV, Heijmans N, Klop O, Zeeman AM, Oostermeijer H, Nieuwenhuis I, Garcia RR, van der Werff NO, Hofman SO, Verreck FAW, Remarque EJ, Faber BW, Kocken CHM. Pasini EM, et al. NPJ Vaccines. 2022 Oct 27;7(1):126. doi: 10.1038/s41541-022-00555-0. NPJ Vaccines. 2022. PMID: 36302860 Free PMC article.

131

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex.

Dagotto G, Ventura JD, Martinez DR, Anioke T, Chung BS, Siamatu M, Barrett J, Miller J, Schäfer A, Yu J, Tostanoski LH, Wagh K, Baric RS, Korber B, Barouch DH. Dagotto G, et al. NPJ Vaccines. 2022 Oct 27;7(1):125. doi: 10.1038/s41541-022-00553-2. NPJ Vaccines. 2022. PMID: 36302778 Free PMC article.

132

CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines.

Nelson SA, Richards KA, Glover MA, Chaves FA, Crank MC, Graham BS, Kanekiyo M, Sant AJ. Nelson SA, et al. NPJ Vaccines. 2022 Oct 26;7(1):124. doi: 10.1038/s41541-022-00547-0. NPJ Vaccines. 2022. PMID: 36289232 Free PMC article.

133

Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines.

Park SY, Levin MJ, Canniff J, Johnson M, Schmid DS, Weinberg A. Park SY, et al. NPJ Vaccines. 2022 Oct 25;7(1):123. doi: 10.1038/s41541-022-00545-2. NPJ Vaccines. 2022. PMID: 36284110 Free PMC article.

134

Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection.

Holder KA, Ings DP, Harnum DOA, Russell RS, Grant MD. Holder KA, et al. NPJ Vaccines. 2022 Oct 21;7(1):122. doi: 10.1038/s41541-022-00546-1. NPJ Vaccines. 2022. PMID: 36271095 Free PMC article.

135

Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus.

Jhajharia S, Lai F, Low HB, Purushotorman K, Shunmuganathan BD, Chan CEZ, Hammond R, Netter HJ, Chen Q, Lim SG, MacAry PA. Jhajharia S, et al. NPJ Vaccines. 2022 Oct 21;7(1):121. doi: 10.1038/s41541-022-00516-7. NPJ Vaccines. 2022. PMID: 36271019 Free PMC article.

136

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant.

Yang N, Garcia A, Meyer C, Tuschl T, Merghoub T, Wolchok JD, Deng L. Yang N, et al. NPJ Vaccines. 2022 Oct 19;7(1):120. doi: 10.1038/s41541-022-00542-5. NPJ Vaccines. 2022. PMID: 36261460 Free PMC article.

137

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.

Ebenig A, Lange MV, Mühlebach MD. Ebenig A, et al. NPJ Vaccines. 2022 Oct 15;7(1):119. doi: 10.1038/s41541-022-00543-4. NPJ Vaccines. 2022. PMID: 36243743 Free PMC article. Review.

138

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern.

Akache B, Renner TM, Stuible M, Rohani N, Cepero-Donates Y, Deschatelets L, Dudani R, Harrison BA, Gervais C, Hill JJ, Hemraz UD, Lam E, Régnier S, Lenferink AEG, Durocher Y, McCluskie MJ. Akache B, et al. NPJ Vaccines. 2022 Oct 12;7(1):118. doi: 10.1038/s41541-022-00540-7. NPJ Vaccines. 2022. PMID: 36224247 Free PMC article.

139

Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates.

Hovakimyan A, Zagorski K, Chailyan G, Antonyan T, Melikyan L, Petrushina I, Batt DG, King O, Ghazaryan M, Donthi A, Foose C, Petrovsky N, Cribbs DH, Agadjanyan MG, Ghochikyan A. Hovakimyan A, et al. NPJ Vaccines. 2022 Oct 12;7(1):117. doi: 10.1038/s41541-022-00544-3. NPJ Vaccines. 2022. PMID: 36224191 Free PMC article.

140

A broadly protective vaccine against cutaneous human papillomaviruses.

Mariz FC, Balz K, Dittrich M, Zhang Y, Yang F, Zhao X, Bolchi A, Ottonello S, Müller M. Mariz FC, et al. NPJ Vaccines. 2022 Oct 10;7(1):116. doi: 10.1038/s41541-022-00539-0. NPJ Vaccines. 2022. PMID: 36216845 Free PMC article.

141

Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants.

Kitagawa S, Matsuda T, Washizaki A, Murakami H, Yamamoto T, Yoshioka Y. Kitagawa S, et al. NPJ Vaccines. 2022 Oct 6;7(1):115. doi: 10.1038/s41541-022-00541-6. NPJ Vaccines. 2022. PMID: 36202858 Free PMC article.

142

Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice.

Saveria T, Parthiban C, Seilie AM, Brady C, Martinez A, Manocha R, Afreen E, Zhao H, Krzeszowski A, Ferrara J, Paddock T, Roberts J, Stone BC, Tasch M, Murphy SC. Saveria T, et al. NPJ Vaccines. 2022 Oct 4;7(1):113. doi: 10.1038/s41541-022-00534-5. NPJ Vaccines. 2022. PMID: 36195607 Free PMC article.

143

Understanding change in COVID-19 vaccination intention with network analysis of longitudinal data from Dutch adults.

Chambon M, Kammeraad WG, van Harreveld F, Dalege J, Elberse JE, van der Maas HLJ. Chambon M, et al. NPJ Vaccines. 2022 Oct 1;7(1):114. doi: 10.1038/s41541-022-00533-6. NPJ Vaccines. 2022. PMID: 36182929 Free PMC article.

144

Dithranol as novel co-adjuvant for non-invasive dermal vaccination.

Sohl J, Hartmann AK, Hahlbrock J, Bartneck J, Stassen M, Klein M, Bros M, Grabbe S, Marini F, Woods K, Guezguez B, Mack M, Schild H, Muth S, Melchior F, Probst HC, Langguth P, Radsak MP. Sohl J, et al. NPJ Vaccines. 2022 Sep 24;7(1):112. doi: 10.1038/s41541-022-00530-9. NPJ Vaccines. 2022. PMID: 36153349 Free PMC article.

145

Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.

Agrati C, Castilletti C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordi L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastri E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Agrati C, et al. NPJ Vaccines. 2022 Sep 24;7(1):111. doi: 10.1038/s41541-022-00531-8. NPJ Vaccines. 2022. PMID: 36153335 Free PMC article.

146

Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity.

Yankowski C, Wirblich C, Kurup D, Schnell MJ. Yankowski C, et al. NPJ Vaccines. 2022 Sep 23;7(1):110. doi: 10.1038/s41541-022-00532-7. NPJ Vaccines. 2022. PMID: 36151100 Free PMC article.

147

Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models.

Ikegami T, Jurado-Cobena E, Alkan C, Smith JK, Zhang L, Kalveram B, Juelich TL, Esterly AT, Bhaskar JR, Thangamani S, Freiberg AN. Ikegami T, et al. NPJ Vaccines. 2022 Sep 21;7(1):109. doi: 10.1038/s41541-022-00536-3. NPJ Vaccines. 2022. PMID: 36131104 Free PMC article.

148

KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine.

Casper C, Corey L, Cohen JI, Damania B, Gershon AA, Kaslow DC, Krug LT, Martin J, Mbulaiteye SM, Mocarski ES, Moore PS, Ogembo JG, Phipps W, Whitby D, Wood C. Casper C, et al. NPJ Vaccines. 2022 Sep 20;7(1):108. doi: 10.1038/s41541-022-00535-4. NPJ Vaccines. 2022. PMID: 36127367 Free PMC article. Review.

149

Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion.

Klafack S, Schröder L, Jin Y, Lenk M, Lee PY, Fuchs W, Avarre JC, Bergmann SM. Klafack S, et al. NPJ Vaccines. 2022 Sep 6;7(1):106. doi: 10.1038/s41541-022-00525-6. NPJ Vaccines. 2022. PMID: 36068296 Free PMC article.

150

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.

Pinpathomrat N, Intapiboon P, Seepathomnarong P, Ongarj J, Sophonmanee R, Hengprakop J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Kongkamol C, Ingviya T, Sangsupawanich P, Chusri S. Pinpathomrat N, et al. NPJ Vaccines. 2022 Sep 6;7(1):107. doi: 10.1038/s41541-022-00529-2. NPJ Vaccines. 2022. PMID: 36068243 Free PMC article. No abstract available.

151

SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN^®, induces robust humoral and cellular immunity in mice and non-human primates.

Alimohammadi R, Porgoo M, Eftekhary M, Kiaie SH, Ansari Dezfouli E, Dehghani M, Nasrollahi K, Malekshahabi T, Heidari M, Pouya S, Alimohammadi M, Sattari Khavas D, Modaresi MS, Ghasemi MH, Ramyar H, Mohammadipour F, Hamzelouei F, Mofayezi A, Mottaghi SS, Rahmati A, Razzaznian M, Tirandazi V, Tat M, Borzouee F, Sadeghi H, Haji Mohammadi M, Rastegar L, Safar Sajadi SM, Ehsanbakhsh H, Bazmbar H, Baghernejadan Z, Shams Nouraei M, Pazooki P, Pahlavanneshan M, Alishah K, Nasiri F, Mokhberian N, Mohammadi SS, Akar S, Niknam H, Azizi M, Ajoudanian M, Moteallehi-Ardakani MH, Mousavi Shaegh SA, Ramezani R, Salimi V, Moazzami R, Hashemi SM, Dehghanizadeh S, Khoddami V. Alimohammadi R, et al. NPJ Vaccines. 2022 Sep 2;7(1):105. doi: 10.1038/s41541-022-00528-3. NPJ Vaccines. 2022. PMID: 36056015 Free PMC article.

152

Publisher Correction: A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.

Olsen AW, Rosenkrands I, Holland MJ, Andersen P, Follmann F. Olsen AW, et al. NPJ Vaccines. 2022 Aug 30;7(1):104. doi: 10.1038/s41541-022-00521-w. NPJ Vaccines. 2022. PMID: 36042252 Free PMC article. No abstract available.

153

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.

Goll JB, Jain A, Jensen TL, Assis R, Nakajima R, Jasinskas A, Coughlan L, Cherikh SR, Gelber CE, Khan S, Huw Davies D, Meade P, Stadlbauer D, Strohmeier S, Krammer F, Chen WH, Felgner PL. Goll JB, et al. NPJ Vaccines. 2022 Aug 30;7(1):103. doi: 10.1038/s41541-022-00524-7. NPJ Vaccines. 2022. PMID: 36042229 Free PMC article.

154

TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination.

Clemens EA, Holbrook BC, McNeilly B, Kanekiyo M, Graham BS, Alexander-Miller MA. Clemens EA, et al. NPJ Vaccines. 2022 Aug 29;7(1):102. doi: 10.1038/s41541-022-00523-8. NPJ Vaccines. 2022. PMID: 36038596 Free PMC article.

155

Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel.

Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Abu Jabal K, Dror AA, Nazzal S, Glikman D, Edelstein M. Kuodi P, et al. NPJ Vaccines. 2022 Aug 26;7(1):101. doi: 10.1038/s41541-022-00526-5. NPJ Vaccines. 2022. PMID: 36028498 Free PMC article.

156

A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection.

Mordmüller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, Bayon PG, Esen M, Gmeiner M, Held J, Heimann HL, Woldearegai TG, Ibáñez J, Flügge J, Fendel R, Kreidenweiss A, Kc N, Murshedkar T, Chakravarty S, Riyahi P, Billingsley PF, Church LWP, Richie TL, Sim BKL, Hoffman SL, Kremsner PG. Mordmüller B, et al. NPJ Vaccines. 2022 Aug 23;7(1):100. doi: 10.1038/s41541-022-00510-z. NPJ Vaccines. 2022. PMID: 35999221 Free PMC article.

157

Author Correction: Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets.

Kim IJ, Lanthier PA, Clark MJ, De La Barrera RA, Tighe MP, Szaba FM, Travis KL, Low-Beer TC, Cookenham TS, Lanzer KG, Bernacki DT, Johnson LL, Schneck AA, Ross CN, Tardif SD, Layne-Colon D, Mdaki SD, Dick EJ Jr, Chuba C, Gonzalez O, Brasky KM, Dutton J, Rutherford JN, Coffey LL, Singapuri A, Martin CSS, Chiu CY, Thomas SJ, Modjarrad K, Patterson JL, Blackman MA. Kim IJ, et al. NPJ Vaccines. 2022 Aug 20;7(1):99. doi: 10.1038/s41541-022-00520-x. NPJ Vaccines. 2022. PMID: 35987764 Free PMC article. No abstract available.

158

Live-attenuated ME49Δcdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis.

Wu M, Liu S, Chen Y, Liu D, An R, Cai H, Wang J, Zhou N, Obed C, Han M, Shen J, Chen L, Du J. Wu M, et al. NPJ Vaccines. 2022 Aug 20;7(1):98. doi: 10.1038/s41541-022-00518-5. NPJ Vaccines. 2022. PMID: 35986017 Free PMC article.

159

Publisher Correction: An immunological autobiography: my year as a COVID-19 vaccine trial participant.

Kedl RM. Kedl RM. NPJ Vaccines. 2022 Aug 19;7(1):97. doi: 10.1038/s41541-022-00522-9. NPJ Vaccines. 2022. PMID: 35986013 Free PMC article. No abstract available.

160

Current status of monkeypox vaccines.

Gruber MF. Gruber MF. NPJ Vaccines. 2022 Aug 17;7(1):94. doi: 10.1038/s41541-022-00527-4. NPJ Vaccines. 2022. PMID: 35977979 Free PMC article. No abstract available.

161

Working correlates of protection predict SchuS4-derived-vaccine candidates with improved efficacy against an intracellular bacterium, Francisella tularensis.

De Pascalis R, Frey B, Rice HM, Bhargava V, Wu TH, Peterson RL, Conlan JW, Sjöstedt A, Elkins KL. De Pascalis R, et al. NPJ Vaccines. 2022 Aug 17;7(1):95. doi: 10.1038/s41541-022-00506-9. NPJ Vaccines. 2022. PMID: 35977964 Free PMC article.

162

Understanding drivers of vaccine hesitancy among pregnant women in Nigeria: A longitudinal study.

Adeyanju GC, Sprengholz P, Betsch C. Adeyanju GC, et al. NPJ Vaccines. 2022 Aug 17;7(1):96. doi: 10.1038/s41541-022-00489-7. NPJ Vaccines. 2022. PMID: 35977958 Free PMC article.

163

A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia.

Sinclair JE, Mayfield HJ, Short KR, Brown SJ, Puranik R, Mengersen K, Litt JCB, Lau CL. Sinclair JE, et al. NPJ Vaccines. 2022 Aug 11;7(1):93. doi: 10.1038/s41541-022-00517-6. NPJ Vaccines. 2022. PMID: 35953502 Free PMC article.

164

Genetic ancestry and population structure of vaccinia virus.

Molteni C, Forni D, Cagliani R, Clerici M, Sironi M. Molteni C, et al. NPJ Vaccines. 2022 Aug 11;7(1):92. doi: 10.1038/s41541-022-00519-4. NPJ Vaccines. 2022. PMID: 35953491 Free PMC article.

165

Author Correction: Antibody responses to the RTS,S/AS01_E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique.

Sánchez L, Vidal M, Jairoce C, Aguilar R, Ubillos I, Cuamba I, Nhabomba AJ, Williams NA, Díez-Padrisa N, Cavanagh D, Angov E, Coppel RL, Gaur D, Beeson JG, Dutta S, Aide P, Campo JJ, Moncunill G, Dobaño C. Sánchez L, et al. NPJ Vaccines. 2022 Aug 8;7(1):91. doi: 10.1038/s41541-022-00515-8. NPJ Vaccines. 2022. PMID: 35941348 Free PMC article. No abstract available.

166

Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans.

Xu S, Carpenter MC, Spreng RL, Neidich SD, Sarkar S, Tenney D, Goodman D, Sawant S, Jha S, Dunn B, Juliana McElrath M, Bekker V, Mudrak SV, Flinko R, Lewis GK, Ferrari G, Tomaras GD, Shen X, Ackerman ME. Xu S, et al. NPJ Vaccines. 2022 Aug 4;7(1):90. doi: 10.1038/s41541-022-00514-9. NPJ Vaccines. 2022. PMID: 35927399 Free PMC article.

167

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame.

Triccas JA, Kint J, Wurm FM. Triccas JA, et al. NPJ Vaccines. 2022 Aug 2;7(1):89. doi: 10.1038/s41541-022-00507-8. NPJ Vaccines. 2022. PMID: 35918346 Free PMC article. No abstract available.

168

mRNA vaccines induce rapid antibody responses in mice.

Gebre MS, Rauch S, Roth N, Gergen J, Yu J, Liu X, Cole AC, Mueller SO, Petsch B, Barouch DH. Gebre MS, et al. NPJ Vaccines. 2022 Aug 1;7(1):88. doi: 10.1038/s41541-022-00511-y. NPJ Vaccines. 2022. PMID: 35915094 Free PMC article.

169

Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.

Nelson AN, Dennis M, Mangold JF, Li K, Saha PT, Cronin K, Cross KA, Kumar A, Mangan RJ, Shaw GM, Bar KJ, Haynes B, Moody AM, Munir Alam S, Pollara J, Hudgens MG, Van Rompay KKA, De Paris K, Permar SR. Nelson AN, et al. NPJ Vaccines. 2022 Jul 30;7(1):87. doi: 10.1038/s41541-022-00505-w. NPJ Vaccines. 2022. PMID: 35907918 Free PMC article.

170

Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease.

Mara AB, Gavitt TD, Tulman ER, Miller JM, He W, Reinhardt EM, Ozyck RG, Goodridge ML, Silbart LK, Szczepanek SM, Geary SJ. Mara AB, et al. NPJ Vaccines. 2022 Jul 29;7(1):86. doi: 10.1038/s41541-022-00513-w. NPJ Vaccines. 2022. PMID: 35906257 Free PMC article.

171

Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.

Tioni MF, Jordan R, Pena AS, Garg A, Wu D, Phan SI, Weiss CM, Cheng X, Greenhouse J, Orekov T, Valentin D, Kar S, Pessaint L, Andersen H, Stobart CC, Bloodworth MH, Stokes Peebles R, Liu Y, Xie X, Shi PY, Moore ML, Tang RS. Tioni MF, et al. NPJ Vaccines. 2022 Jul 29;7(1):85. doi: 10.1038/s41541-022-00509-6. NPJ Vaccines. 2022. PMID: 35906244 Free PMC article.

172

Rational development of a combined mRNA vaccine against COVID-19 and influenza.

Ye Q, Wu M, Zhou C, Lu X, Huang B, Zhang N, Zhao H, Chi H, Zhang X, Ling D, Zhang RR, Li Z, Luo D, Huang YJ, Qiu HY, Song H, Tan W, Xu K, Ying B, Qin CF. Ye Q, et al. NPJ Vaccines. 2022 Jul 26;7(1):84. doi: 10.1038/s41541-022-00478-w. NPJ Vaccines. 2022. PMID: 35882870 Free PMC article.

173

Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2.

Taddeo A, Veiga IB, Devisme C, Boss R, Plattet P, Weigang S, Kochs G, Thiel V, Benarafa C, Zimmer G. Taddeo A, et al. NPJ Vaccines. 2022 Jul 25;7(1):82. doi: 10.1038/s41541-022-00508-7. NPJ Vaccines. 2022. PMID: 35879345 Free PMC article.

174

A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection.

Malherbe DC, Domi A, Hauser MJ, Atyeo C, Fischinger S, Hyde MA, Williams JM, Alter G, Guirakhoo F, Bukreyev A. Malherbe DC, et al. NPJ Vaccines. 2022 Jul 25;7(1):83. doi: 10.1038/s41541-022-00512-x. NPJ Vaccines. 2022. PMID: 35879311 Free PMC article.

175

A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice.

Strohmeier S, Amanat F, Campbell JD, Traquina P, Coffman RL, Krammer F. Strohmeier S, et al. NPJ Vaccines. 2022 Jul 22;7(1):81. doi: 10.1038/s41541-022-00486-w. NPJ Vaccines. 2022. PMID: 35869085 Free PMC article.

176

An immunological autobiography: my year as a COVID-19 vaccine trial participant.

Kedl RM. Kedl RM. NPJ Vaccines. 2022 Jul 18;7(1):80. doi: 10.1038/s41541-022-00502-z. NPJ Vaccines. 2022. PMID: 35851389 Free PMC article.

177

Antigenic comparison of the neuraminidases from recent influenza A vaccine viruses and 2019-2020 circulating strains.

Gao J, Li X, Klenow L, Malik T, Wan H, Ye Z, Daniels R. Gao J, et al. NPJ Vaccines. 2022 Jul 14;7(1):79. doi: 10.1038/s41541-022-00500-1. NPJ Vaccines. 2022. PMID: 35835790 Free PMC article.

178

Vaccine-induced time- and age-dependent mucosal immunity to gastrointestinal parasite infection.

Liu W, McNeilly TN, Mitchell M, Burgess STG, Nisbet AJ, Matthews JB, Babayan SA. Liu W, et al. NPJ Vaccines. 2022 Jul 7;7(1):78. doi: 10.1038/s41541-022-00501-0. NPJ Vaccines. 2022. PMID: 35798788 Free PMC article.

179

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S.

Barbeau DJ, Martin JM, Carney E, Dougherty E, Doyle JD, Dermody TS, Hoberman A, Williams JV, Michaels MG, Alcorn JF, Paul Duprex W, McElroy AK. Barbeau DJ, et al. NPJ Vaccines. 2022 Jul 6;7(1):77. doi: 10.1038/s41541-022-00504-x. NPJ Vaccines. 2022. PMID: 35794181 Free PMC article.

180

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis.

Kehr S, Berg P, Müller S, Fiedler SA, Meyer B, Ruppert-Seipp G, Witzenhausen C, Wolf ME, Henkes HH, Oberle D, Keller-Stanislawski B, Funk MB. Kehr S, et al. NPJ Vaccines. 2022 Jul 5;7(1):76. doi: 10.1038/s41541-022-00491-z. NPJ Vaccines. 2022. PMID: 35790739 Free PMC article.

181

The use of viral vectors in vaccine development.

Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. Travieso T, et al. NPJ Vaccines. 2022 Jul 4;7(1):75. doi: 10.1038/s41541-022-00503-y. NPJ Vaccines. 2022. PMID: 35787629 Free PMC article. Review.

182

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle.

Rainho-Tomko JN, Pavot V, Kishko M, Swanson K, Edwards D, Yoon H, Lanza L, Alamares-Sapuay J, Osei-Bonsu R, Mundle ST, Murison DA, Gallichan S, Delagrave S, Wei CJ, Zhang L, Nabel GJ. Rainho-Tomko JN, et al. NPJ Vaccines. 2022 Jun 30;7(1):74. doi: 10.1038/s41541-022-00487-9. NPJ Vaccines. 2022. PMID: 35773301 Free PMC article.

183

Rapid generation of Shigella flexneri GMMA displaying natural or new and cross-reactive O-Antigens.

Gasperini G, Raso MM, Schiavo F, Aruta MG, Ravenscroft N, Bellich B, Cescutti P, Necchi F, Rappuoli R, Micoli F. Gasperini G, et al. NPJ Vaccines. 2022 Jun 30;7(1):69. doi: 10.1038/s41541-022-00497-7. NPJ Vaccines. 2022. PMID: 35773292 Free PMC article.

184

A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine.

Subbiah J, Oh J, Kim KH, Shin CH, Park BR, Bhatnagar N, Seong BL, Wang BZ, Kang SM. Subbiah J, et al. NPJ Vaccines. 2022 Jun 29;7(1):68. doi: 10.1038/s41541-022-00498-6. NPJ Vaccines. 2022. PMID: 35768475 Free PMC article.

185

Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France.

Taha S, Taha MK, Deghmane AE. Taha S, et al. NPJ Vaccines. 2022 Jun 29;7(1):73. doi: 10.1038/s41541-022-00488-8. NPJ Vaccines. 2022. PMID: 35768437 Free PMC article.

186

Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies.

Hameed SA, Paul S, Dellosa GKY, Jaraquemada D, Bello MB. Hameed SA, et al. NPJ Vaccines. 2022 Jun 28;7(1):71. doi: 10.1038/s41541-022-00485-x. NPJ Vaccines. 2022. PMID: 35764661 Free PMC article. Review.

187

Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2.

Park HS, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, Ahlers LRH, Moore IN, Afroz S, Johnson RF, Lafont BAP, Dorward DW, Fischer ER, Martens C, Samal SK, Munir S, Buchholz UJ, Le Nouën C. Park HS, et al. NPJ Vaccines. 2022 Jun 28;7(1):72. doi: 10.1038/s41541-022-00493-x. NPJ Vaccines. 2022. PMID: 35764659 Free PMC article.

188

The C3d-fused foot-and-mouth disease vaccine platform overcomes maternally-derived antibody interference by inducing a potent adaptive immunity.

Lee MJ, Kim HM, Shin S, Jo H, Park SH, Kim SM, Park JH. Lee MJ, et al. NPJ Vaccines. 2022 Jun 28;7(1):70. doi: 10.1038/s41541-022-00496-8. NPJ Vaccines. 2022. PMID: 35764653 Free PMC article.

189

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses.

Ertesvåg NU, Cox RJ, Lartey SL, Mohn KG, Brokstad KA, Trieu MC. Ertesvåg NU, et al. NPJ Vaccines. 2022 Jun 24;7(1):67. doi: 10.1038/s41541-022-00490-0. NPJ Vaccines. 2022. PMID: 35750781 Free PMC article.

190

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.

Flickinger JC Jr, Staudt RE, Singh J, Carlson RD, Barton JR, Baybutt TR, Rappaport JA, Zalewski A, Pattison A, Waldman SA, Snook AE. Flickinger JC Jr, et al. NPJ Vaccines. 2022 Jun 23;7(1):61. doi: 10.1038/s41541-022-00483-z. NPJ Vaccines. 2022. PMID: 35739202 Free PMC article.

191

An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets.

Bullard BL, DeBeauchamp J, Pekarek MJ, Petro-Turnquist E, Vogel P, Webby RJ, Weaver EA. Bullard BL, et al. NPJ Vaccines. 2022 Jun 23;7(1):65. doi: 10.1038/s41541-022-00492-y. NPJ Vaccines. 2022. PMID: 35739199 Free PMC article.

192

Engineering the hydroxyl content on aluminum oxyhydroxide nanorod for elucidating the antigen adsorption behavior.

Yu G, Liang Z, Yu Z, Li M, Yang W, Zhang Y, Zhao Y, Yang C, Xue C, Shi L, Sun B. Yu G, et al. NPJ Vaccines. 2022 Jun 23;7(1):62. doi: 10.1038/s41541-022-00495-9. NPJ Vaccines. 2022. PMID: 35739192 Free PMC article.

193

Humoral response to anti-SARS-CoV-2 vaccine in breastfeeding mothers and mother-to-infant antibody transfer through breast milk.

Pietrasanta C, Darwich A, Ronchi A, Crippa B, Spada E, Mosca F, Pugni L, Rescigno M. Pietrasanta C, et al. NPJ Vaccines. 2022 Jun 23;7(1):63. doi: 10.1038/s41541-022-00499-5. NPJ Vaccines. 2022. PMID: 35739127 Free PMC article.

194

Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control.

Tondini E, Reintjens NRM, Castello G, Arakelian T, Isendoorn M, Camps M, Vree J, van der Marel GA, Filippov DV, Codee JDC, Ossendorp F. Tondini E, et al. NPJ Vaccines. 2022 Jun 23;7(1):64. doi: 10.1038/s41541-022-00484-y. NPJ Vaccines. 2022. PMID: 35739113 Free PMC article.

195

Live attenuated pertussis vaccine for prevention and treatment of allergic airway inflammation in mice.

Belcher T, Ait-Yahia S, Solans L, Debrie AS, Cauchi S, Tsicopoulos A, Locht C. Belcher T, et al. NPJ Vaccines. 2022 Jun 23;7(1):66. doi: 10.1038/s41541-022-00494-w. NPJ Vaccines. 2022. PMID: 35739108 Free PMC article.

196

A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection.

Tzeng TT, Chai KM, Shen KY, Yu CY, Yang SJ, Huang WC, Liao HC, Chiu FF, Dou HY, Liao CL, Chen HW, Liu SJ. Tzeng TT, et al. NPJ Vaccines. 2022 Jun 3;7(1):60. doi: 10.1038/s41541-022-00482-0. NPJ Vaccines. 2022. PMID: 35662254 Free PMC article.

197

Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens.

Ibanez J, Fendel R, Lorenz FR, Granados-Bayon P, Brückner S, Esen M, Sulyok M, Sulyok Z, Borrmann S, Bacher P, Scheffold A, Hoffman SL, Kremsner PG, Mordmüller B. Ibanez J, et al. NPJ Vaccines. 2022 May 31;7(1):59. doi: 10.1038/s41541-022-00473-1. NPJ Vaccines. 2022. PMID: 35641527 Free PMC article.

198

Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies.

Wilder BK, Vigdorovich V, Carbonetti S, Minkah N, Hertoghs N, Raappana A, Cardamone H, Oliver BG, Trakhimets O, Kumar S, Dambrauskas N, Arredondo SA, Camargo N, Seilie AM, Murphy SC, Kappe SHI, Sather DN. Wilder BK, et al. NPJ Vaccines. 2022 May 26;7(1):58. doi: 10.1038/s41541-022-00480-2. NPJ Vaccines. 2022. PMID: 35618791 Free PMC article.

199

Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease.

Davenport BJ, Catala A, Weston SM, Johnson RM, Ardanuy J, Hammond HL, Dillen C, Frieman MB, Catalano CE, Morrison TE. Davenport BJ, et al. NPJ Vaccines. 2022 May 26;7(1):57. doi: 10.1038/s41541-022-00481-1. NPJ Vaccines. 2022. PMID: 35618725 Free PMC article.

200

Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism.

Bachmann MF, Mohsen MO, Speiser DE. Bachmann MF, et al. NPJ Vaccines. 2022 May 25;7(1):56. doi: 10.1038/s41541-022-00479-9. NPJ Vaccines. 2022. PMID: 35614112 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

686 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

686 results

Results by year